Efficacy and Safety of Neoadjuvant Immunochemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Neoadjuvant ICT enhances short-term pathologic and tumor responses in LA-SCCHN versus neoadjuvant chemotherapy, but increases toxicity and lacks proven survival benefits. Further high-quality trials are needed to optimize ICT regimens and identify predictive biomarkers.
Authors
- Li Chai (ORCID: https://orcid.org/0000-0003-1937-4750)
- L Zhang
- Chang Xu (ORCID: https://orcid.org/0000-0003-2737-4312)
- Hui Qiu
- Gongzhen Liu
Institutions
- Xuzhou Medical College (CN)
- Cancer Institute (WIA) (IN)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2026-02-11
- DOI
- https://doi.org/10.1097/coc.0000000000001304
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00